Study summary · research use only
[Immunotherapy of pulmonary tuberculosis]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This observational study in humans comparatively analyzed different immune correctors used alongside treatment for destructive pulmonary tuberculosis. Five hundred and fifty three patients were treated with thymalin, thymogen, human leukocytic interferon, or a combination of thymogen and interferon. The authors report that benefit from immunocorrector treatment was obtained early in the complex therapy and that, in their analysis, the combination of thymogen plus interferon gave the best result. They also describe the action of the two immunocorrectors as increasing once fibrous deformity of the lung had healed, followed by the development of pronounced residual changes. The abstract gives no comparative statistics.
Abstract
The efficiency of treating patients with destructive tuberculosis by using different immune correctors was comparatively analyzed. Five hundred and fifty three patients were treated with thymalin, thymogen, human leukocytic interferon, and a combination of thymogen and interferon. The benefit from immunocorrector treatment was obtained early in the complex therapy and the best result was achieved by the use of thymogen plus interferon. However, the action of the two immunocorrectors increased when fibrous deformity of the lung was healed, followed by the development of pronounced residual changes.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.